Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT)
Journal of Neuro-Oncology · 2024
DOI: 10.1007/s11060-024-04708-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2024. Verfasst von Yasamin Yousefi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Temozolomide, Antineoplastic Agents, Alkylating, CRISPR-Cas Systems, Down-Regulation. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Glioblastoma (GBM) stands out as the most prevalent and aggressive intracranial tumor, notorious for its poor prognosis. The current standard-of-care for GBM patients involves surgical resection followed by radiotherapy, combined with concurrent and adjuvant chemotherapy using Temozolomide (TMZ). The effectiveness of TMZ primarily relies on the activity of O6-methylguanine DNA methyltransferase (MGMT), which removes alkyl adducts from the O6 position of guanine at the DNA level, thereby counteracting the toxic effects of TMZ. METHOD: In this study, we employed fusions of catalytically-inactive Cas9 (dCas9) to DNA methyltransferases (dCas9-DNMT3A) to selectively downregulation MGMT transcription by inducing methylation at MGMT promoter and K-M enhancer. RESULT: Our findings demonstrate a significant reduction in MGMT expression, leading to intensified TMZ sensitivity in the HEK293T cell line. CONCLUSION: This study serves as a proof of concept for the utilization of CRISPR-based gene suppression to overcome TMZ resistance and enhance the lethal effect of TMZ in glioblastoma tumor cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
- Department of Pathology, Fox Chase Cancer Center, Temple University Health System, 19111, Philadelphia, PA, USA.
- Department of chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran. Asoodeh@um.ac.ir.
- Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. mojaradm@mums.ac.ir.
Zitieren
APA
Yousefi, Y., Nejati, R., Eslahi, A., Alizadeh, F., Farrokhi, S., Asoodeh, A., & Mojarrad, M. (2024). Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT). Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04708-0
Vancouver
Yousefi Y, Nejati R, Eslahi A, Alizadeh F, Farrokhi S, Asoodeh A, et al. Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT). Journal of Neuro-Oncology. 2024. doi:10.1007/s11060-024-04708-0
BibTeX
@article{Yousefi2024,
author = {Yousefi, Yasamin and Nejati, Reza and Eslahi, Atiye and Alizadeh, Farzaneh and Farrokhi, Shima and Asoodeh, Ahmad and Mojarrad, Majid},
title = {Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT)},
journal = {Journal of Neuro-Oncology},
year = {2024},
doi = {10.1007/s11060-024-04708-0}
}
EUVIMED